FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 336:1041-1045 April 10, 1997 Number 15 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Photochemotherapy with oral methoxsalen (psoralen) and ultraviolet A radiation (PUVA) is an effective treatment for psoriasis. However, PUVA is mutagenic, increases the risk of squamous-cell skin cancer, and can cause irregular, pigmented skin lesions. We studied the occurrence of melanoma among patients treated with PUVA.

Methods We prospectively identified cases of melanoma and documented the extent of exposure to PUVA among 1380 patients with psoriasis who were first treated with PUVA in 1975 or 1976. Using incidence data, we calculated the expected incidence of melanoma in this cohort and compared it with the observed incidence. Using regression models, we assessed the risks of melanoma associated with a long time (>15 years) since the first treatment and with a large number of PUVA treatments (>250).

Results From 1975 through 1990, we detected four malignant melanomas, about the number expected in the overall population (relative risk, 1.1). From 1991 through 1996, we detected seven malignant melanomas (relative risk, 5.4; 95 percent confidence interval, 2.2 to 11.1). The risk of melanoma was higher in the later period than in the earlier one (incidence-rate ratio, 3.8) and higher among patients who received at least 250 PUVA treatments than among those who received fewer treatments (incidence-rate ratio, 3.1).

Conclusions About 15 years after the first treatment with PUVA, the risk of malignant melanoma increases, especially among patients who receive 250 treatments or more.

Source Information

From the Department of Dermatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston.

Address reprint requests to Dr. Stern at 330 Brookline Ave., Boston, MA 02215.

Full Text of this Article

Related Letters:

Melanoma after PUVA Therapy for Psoriasis
Whitmore S. E., Morison W. L., Stern R. S.
Extract | Full Text  
N Engl J Med 1997; 337:502-503, Aug 14, 1997. Correspondence

This article has been cited by other articles:

• Gelfand, J. M. (2007). Long-term Treatment for Severe Psoriasis: We're Halfway There, With a Long Way to Go. Arch Dermatol 143: 1191-1193 [Full Text]  
• Stern, R. S. (2007). Psoralen and Ultraviolet A Light Therapy for Psoriasis. NEJM 357: 682-690 [Full Text]  
• Costin, G.-E., Hearing, V. J. (2007). Human skin pigmentation: melanocytes modulate skin color in response to stress. FASEB J. 21: 976-994 [Abstract] [Full Text]  
• Gallagher, R. P., Spinelli, J. J., Lee, T. K. (2005). Tanning Beds, Sunlamps, and Risk of Cutaneous Malignant Melanoma. Cancer Epidemiol. Biomarkers Prev. 14: 562-566 [Abstract] [Full Text]  
• Querfeld, C., Rosen, S. T., Kuzel, T. M., Kirby, K. A., Roenigk, H. H. Jr, Prinz, B. M., Guitart, J. (2005). Long-term Follow-up of Patients With Early-Stage Cutaneous T-Cell Lymphoma Who Achieved Complete Remission With Psoralen Plus UV-A Monotherapy. Arch Dermatol 141: 305-311 [Abstract] [Full Text]  
• Lebwohl, M, Ting, P T, Koo, J Y M (2005). Psoriasis treatment: traditional therapy. Ann Rheum Dis 64: ii83-ii86 [Abstract] [Full Text]  
• Elder, J. T (2005). Psoriasis clinical registries, genetics, and genomics. Ann Rheum Dis 64: ii106-ii107 [Abstract] [Full Text]  
• Lambertini, L., Surin, K., Ton, T.-V. T., Clayton, N., Dunnick, J. K., Kim, Y., Hong, H.-H. L., Devereux, T. R., Sills, R. C. (2005). Analysis of p53 Tumor Suppressor Gene, H-ras Protooncogene and Proliferating Cell Nuclear Antigen (PCNA) in Squamous Cell Carcinomas of HRA/Skh Mice Following Exposure to 8-Methoxypsoralen (8-MOP) and UVA Radiation (PUVA Therapy). Toxicol Pathol 33: 292-299 [Abstract] [Full Text]  
• Lazovich, D., Forster, J., Sorensen, G., Emmons, K., Stryker, J., Demierre, M.-F., Hickle, A., Remba, N. (2004). Characteristics Associated With Use or Intention to Use Indoor Tanning Among Adolescents. Arch Pediatr Adolesc Med 158: 918-924 [Abstract] [Full Text]  
• Boehncke, W.-H. (2003). Immunomodulatory drugs for psoriasis. BMJ 327: 634-635 [Full Text]  
• Lebwohl, M. (2002). New Developments in the Treatment of Psoriasis. Arch Dermatol 138: 686-688 [Full Text]  
• Mulvihill, N T, Foley, J B (2002). Inflammation in acute coronary syndromes. Heart 87: 201-204 [Abstract] [Full Text]  
• Margolis, D., Bilker, W., Hennessy, S., Vittorio, C., Santanna, J., Strom, B. L. (2001). The Risk of Malignancy Associated With Psoriasis. Arch Dermatol 137: 778-783 [Abstract] [Full Text]  
• Clark, C., Dawe, R. S., Evans, A. T., Lowe, G., Ferguson, J. (2000). Narrowband TL-01 Phototherapy for Patch-Stage Mycosis Fungoides. Arch Dermatol 136: 748-752 [Abstract] [Full Text]  
• Goldstein, A. E., Lebwohl, M., Wei, H. (2000). Comparison of Urinary 8-Hydroxy-2'-deoxyguanosine in Patients Treated With Topical Corticosteroids, UV-B, and Psoralen UV-A Therapies. Arch Dermatol 136: 808-810 [Full Text]  
• Hoeger, P. H, Nanduri, V. R, Harper, J. I, Atherton, D. A, Pritchard, J. (2000). Long term follow up of topical mustine treatment for cutaneous Langerhans cell histiocytosis. Arch. Dis. Child. 82: 483-487 [Abstract] [Full Text]  
• Monti, P., Inga, A., Aprile, A., Campomenosi, P., Menichini, P., Ottaggio, L., Viaggi, S., Ghigliotti, G., Abbondandolo, A., Fronza, G. (2000). p53 mutations experimentally induced by 8-methoxypsoralen plus UVA (PUVA) differ from those found in human skin cancers in PUVA-treated patients. Mutagenesis 15: 127-132 [Abstract] [Full Text]  
• Boehncke, W.-H., Elshorst-Schmidt, T., Kaufmann, R. (2000). Systemic Photodynamic Therapy Is a Safe and Effective Treatment for Psoriasis. Arch Dermatol 136: 271-272 [Full Text]  
• Murphy, F. P., Coven, T. R., Burack, L. H., Gilleaudeau, P., Cardinale, I., Auerbach, R., Krueger, J. G. (1999). Clinical Clearing of Psoriasis by 6-Thioguanine Correlates With Cutaneous T-Cell Depletion via Apoptosis: Evidence for Selective Effects on Activated T Lymphocytes. Arch Dermatol 135: 1495-1502 [Abstract] [Full Text]  
• Stern, R. S., Beer, J. Z., Mills, D. K. (1999). Lack of Consensus Among Experts on the Choice of UV Therapy for Psoriasis. Arch Dermatol 135: 1187-1192 [Abstract] [Full Text]  
• Taylor, C. R., Kwangsukstith, C., Wimberly, J., Kollias, N., Anderson, R. R. (1999). Turbo-PUVA: Dihydroxyacetone-Enhanced Photochemotherapy for Psoriasis: A Pilot Study. Arch Dermatol 135: 540-544 [Abstract] [Full Text]  
• Ritchie, M. E. (1998). Nuclear Factor-{kappa}B Is Selectively and Markedly Activated in Humans With Unstable Angina Pectoris. Circulation 98: 1707-1713 [Abstract] [Full Text]  
• Lunder, E. J., Stern, R. S. (1998). Merkel-Cell Carcinomas in Patients Treated with Methoxsalen and Ultraviolet A Radiation. NEJM 339: 1247-1248 [Full Text]  
• Coven, T. R., Murphy, F. P., Gilleaudeau, P., Cardinale, I., Krueger, J. G. (1998). Trimethylpsoralen Bath PUVA Is a Remittive Treatment for Psoriasis Vulgaris: Evidence That Epidermal Immunocytes Are Direct Therapeutic Targets. Arch Dermatol 134: 1263-1268 [Abstract] [Full Text]  
• Zackheim, H. S., Kashani-Sabet, M., Amin, S. (1998). Topical Corticosteroids for Mycosis Fungoides: Experience in 79 Patients. Arch Dermatol 134: 949-954 [Abstract] [Full Text]  
• Gasparro, F. P. (1998). p53 in Dermatology. Arch Dermatol 134: 1029-1032 [Full Text]  
• Morison, W. L., Baughman, R. D., Day, R. M., Forbes, P. D., Hoenigsmann, H., Krueger, G. G., Lebwohl, M., Lew, R., Naldi, L., Parrish, J. A., Piepkorn, M., Stern, R. S., Weinstein, G. D., Whitmore, S. E. (1998). Consensus Workshop on the Toxic Effects of Long-term PUVA Therapy. Arch Dermatol 134: 595-598 [Abstract] [Full Text]  
• Whitmore, S. E., Morison, W. L., Stern, R. S. (1997). Melanoma after PUVA Therapy for Psoriasis. NEJM 337: 502-503 [Full Text]  
• (1997). PUVA and Malignant Melanoma. Journal Watch Dermatology 1997: 1-1 [Full Text]  
• Wolff, K. (1997). Should PUVA Be Abandoned?. NEJM 336: 1090-1091 [Full Text]